Advances in human B19 erythrovirus biology

Journal of Virology

Volumn 84, Issue 19, 2010, Pages 9658-9665

  Servant Delmas, Annabelle ^a   Lefrère, Jean Jacques ^a,b   Morinet, Frédéric ^c   Pillet, Sylvie ^d,e  

^a INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^e UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEOTIDE; VIRUS DNA;

APOPTOSIS; ARTHRITIS; CARDIOVASCULAR INFECTION; CELL CYCLE; CENTRAL NERVOUS SYSTEM INFECTION; DISEASE ASSOCIATION; ERYTHEMA INFECTIOSUM; ERYTHROBLASTOPENIA; GENETIC VARIABILITY; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN PARVOVIRUS B19; IMMUNE DEFICIENCY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SHORT SURVEY; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS GENOME; VIRUS INFECTION; VIRUS REPLICATION; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; MOLECULAR EPIDEMIOLOGY; PARVOVIRIDAE INFECTIONS; PATHOGENICITY; PHYLOGENY; PHYSIOLOGY; ULTRASTRUCTURE; VIROLOGY;

ERYTHROVIRUS; PARVOVIRUS;

APOPTOSIS; GENETIC VARIATION; HOST-PATHOGEN INTERACTIONS; HUMANS; MOLECULAR EPIDEMIOLOGY; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; PHYLOGENY; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 77956800437     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00684-10     Document Type: Short Survey

References (103)

1. Agbandje, M., S. Kajigaya, R. McKenna, N. S. Young, and M. G. Rossmann. 1994. The structure of human parvovirus B19 at 8 Å resolution. Virology 203:106-115.
2. Allander, T., M. T. Tammi, M. Eriksson, A. Bjerkner, A. Tiveljung-Lindell, and B. Andersson. 2005. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc. Natl. Acad. Sci. U. S. A. 102:12891-12896.
3. Anderson, M. J., P. G. Higgins, L. R. Davis, J. S. Willman, S. E. Jones, I. M. Kidd, J. R. Pattison, and D. A. Tyrrell. 1985. Experimental parvoviral infection in humans. J. Infect. Dis. 152:257-265.
4. Bock, C. T., K. Klingel, S. Aberle, A. Duechting, A. Lupescu, F. Lang, and R. Kandolf. 2005. Human parvovirus B19: a new emerging pathogen of inflammatory cardiomyopathy. J. Vet. Med. B Infect. Dis. Vet. Public Health 52:340-343.
5. Bock, C. T., K. Klingel, and R. Kandolf. 2010. Human parvovirus B19- associated myocarditis. N. Engl. J. Med. 362:1248-1249.
6. Bönsch, C., C. Kempf, I. Mueller, L. Manning, M. Laman, T. M. Davis, and C. Ros. 2010. Chloroquine and its derivatives exacerbate B19V-associated anemia by promoting viral replication. PLoS Negl. Trop. Dis. 4:e669.
7. Brown, K. E. 1997. Human parvovirus B19 epidemiology and clinical manifestations, p. 42-55. In L. J. Anderson and N. S. Young (ed.), Human parvovirus B19, 1st ed., vol. 20. Karger, New York, NY.
8. Brown, K. E., S. M. Anderson, and N. S. Young. 1993. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 262:114-117.
9. Brown, K. E., J. R. Hibbs, G. Gallinella, S. M. Anderson, E. D. Lehman, P. McCarthy, and N. S. Young. 1994. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N. Engl. J. Med. 330:1192-1196.
10. Canaan, S., Z. Zadori, F. Ghomashchi, J. Bollinger, M. Sadilek, M. E. Moreau, P. Tijssen, and M. H. Gelb. 2004. Interfacial enzymology of parvovirus phospholipases A2. J. Biol. Chem. 279:14502-14508.
11. Candotti, D., N. Etiz, A. Parsyan, and J. P. Allain. 2004. Identification and characterization of persistent human erythrovirus infection in blood donor samples. J. Virol. 78:12169-12178.
12. Cassinotti, P., G. Burtonboy, M. Fopp, and G. Siegl. 1997. Evidence for persistence of human parvovirus B19 DNA in bone marrow. J. Med. Virol. 53:229-232.
13. Cassinotti, P., and G. Siegl. 2000. Quantitative evidence for persistence of human parvovirus B19 DNA in an immunocompetent individual. Eur. J. Clin. Microbiol. Infect. Dis. 19:886-887.
14. Chen, A. Y., E. Y. Zhang, W. Guan, F. Cheng, S. Kleiboeker, T. M. Yankee, and J. Qiu. 2010. The small 11 kDa nonstructural protein of human parvovirus B19 plays a key role in inducing apoptosis during B19 virus infection of primary erythroid progenitor cells. Blood 115:1070-1080.
15. Chen, Z., W. Guan, F. Cheng, A. Y. Chen, and J. Qiu. 2009. Molecular characterization of human parvovirus B19 genotypes 2 and 3. Virology 394:276-285.
16. Chipman, P. R., M. Agbandje-McKenna, S. Kajigaya, K. E. Brown, N. S. Young, T. S. Baker, and M. G. Rossmann. 1996. Cryo-electron microscopy studies of empty capsids of human parvovirus B19 complexed with its cellular receptor. Proc. Natl. Acad. Sci. U. S. A. 93:7502-7506.
17. Cohen, B. J., S. Beard, W. A. Knowles, J. S. Ellis, D. Joske, J. M. Goldman, P. Hewitt, and K. N. Ward. 1997. Chronic anemia due to parvovirus B19 infection in a bone marrow transplant patient after platelet transfusion. Transfusion 37:947-952.
18. Corbau, R., V. Duverger, J. Rommelaere, and J. P. Nuesch. 2000. Regulation of MVM NS1 by protein kinase C: impact of mutagenesis at consensus phosphorylation sites on replicative functions and cytopathic effects. Virology 278:151-167.
19. Cossart, Y. E., A. M. Field, B. Cant, and D. Widdows. 1975. Parvovirus-like particles in human sera. Lancet i:72-73.
20. Cotmore, S. F., and P. Tattersall. 2007. Parvoviral host range and cell entry mechanisms. Adv. Virus Res. 70:183-232.
21. Dorsch, S., G. Liebisch, B. Kaufmann, P. von Landenberg, J. H. Hoffmann, W. Drobnik, and S. Modrow. 2002. The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. J. Virol. 76:2014-2018. (Pubitemid 34094651)
22. Douvoyiannis, M., N. Litman, and D. L. Goldman. 2009. Neurologic manifestations associated with parvovirus B19 infection. Clin. Infect. Dis. 48: 1713-1723.
23. Duechting, A., C. Tschope, H. Kaiser, T. Lamkemeyer, K. Tanaka, S. Aberle, F. Lang, J. Torresi, R. Kandolf, and C. T. Bock. 2008. Human parvovirus B19 NS1 protein modulates inflammatory signaling by activation of STAT3/PIAS3 in human endothelial cells. J. Virol. 82:7942-7952.
24. Fan, M. M., L. Tamburic, C. Shippam-Brett, D. B. Zagrodney, and C. R. Astell. 2001. The small 11-kDa protein from B19 parvovirus binds growth factor receptor-binding protein 2 in vitro in a Src homology 3 domain/ ligand-dependent manner. Virology 291:285-291.
25. Reference deleted.
26. Filippone, C., R. Franssila, A. Kumar, L. Saikko, P. E. Kovanen, M. Soderlund-Venermo, and K. Hedman. 2010. Erythroid progenitor cells expanded from peripheral blood without mobilization or preselection: molecular characteristics and functional competence. PLoS One 5:e9496.
27. Filippone, C., N. Zhi, S. Wong, J. Lu, S. Kajigaya, G. Gallinella, L. Kakkola, M. Soderlund-Venermo, N. S. Young, and K. E. Brown. 2008. VP1u phospholipase activity is critical for infectivity of full-length parvovirus B19 genomic clones. Virology 374:444-452.
28. Flunker, G., A. Peters, S. Wiersbitzky, S. Modrow, and W. Seidel. 1998. Persistent parvovirus B19 infections in immunocompromised children. Med. Microbiol. Immunol. 186:189-194.
29. Frickhofen, N., J. L. Abkowitz, M. Safford, J. M. Berry, J. Antunez-de-Mayolo, A. Astrow, R. Cohen, I. Halperin, L. King, and D. Mintzer. 1990. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann. Intern. Med. 113:926-933.
30. Fu, Y., K. K. Ishii, Y. Munakata, T. Saitoh, M. Kaku, and T. Sasaki. 2002. Regulation of tumor necrosis factor alpha promoter by human parvovirus B19 NS1 through activation of AP-1 and AP-2. J. Virol. 76:5395-5403.
31. Gallinella, G., E. Manaresi, E. Zuffi, S. Venturoli, L. Bonsi, G. P. Bagnara, M. Musiani, and M. Zerbini. 2000. Different patterns of restriction to B19 parvovirus replication in human blast cell lines. Virology 278:361-367. (Pubitemid 32012771)
32. Guan, W., F. Cheng, Y. Yoto, S. Kleiboeker, S. Wong, N. Zhi, D. J. Pintel, and J. Qiu. 2008. Block to the production of full-length B19 virus transcripts by internal polyadenylation is overcome by replication of the viral genome. J. Virol. 82:9951-9963.
33. Guan, W., S. Wong, N. Zhi, and J. Qiu. 2009. The genome of human parvovirus B19 can replicate in nonpermissive cells with the help of adenovirus genes and produces infectious virus. J. Virol. 83:9541-9553.
34. Guo, Y. M., K. Ishii, M. Hirokawa, H. Tagawa, H. Ohyagi, Y. Michishita, K. Ubukawa, J. Yamashita, T. Ohteki, N. Onai, K. Kawakami, W. Xiao, and K. Sawada. 2010. CpG-ODN 2006 and human parvovirus B19 genome consensus sequences selectively inhibit growth and development of erythroid progenitor cells. Blood 115:4569-4579.
35. Harbison, C. E., J. A. Chiorini, and C. R. Parrish. 2008. The parvovirus capsid odyssey: from the cell surface to the nucleus. Trends Microbiol. 16:208-214.
36. Hemauer, A., K. Beckenlehner, H. Wolf, B. Lang, and S. Modrow. 1999. Acute parvovirus B19 infection in connection with a flare of systemic lupus erythematodes in a female patient. J. Clin. Virol. 14:73-77.
37. Hokynar, K., P. Norja, H. Laitinen, P. Palomaki, A. Garbarg-Chenon, A. Ranki, K. Hedman, and M. Soderlund-Venermo. 2004. Detection and differentiation of human parvovirus variants by commercial quantitative realtime PCR tests. J. Clin. Microbiol. 42:2013-2019.
38. Hokynar, K., M. Soderlund-Venermo, M. Pesonen, A. Ranki, O. Kiviluoto, E. K. Partio, and K. Hedman. 2002. A new parvovirus genotype persistent in skin. Virology 302:224-228.
39. Hübschen, J. M., Z. Mihneva, A. F. Mentis, F. Schneider, Y. Aboudy, Z. Grossman, H. Rudich, K. Kasymbekova, I. Sarv, J. Nedeljkovic, M. C. Tahita, Z. Tarnagda, J. B. Ouedraogo, A. G. Gerasimova, T. N. Moskaleva, N. T. Tikhonova, N. Chitadze, J. C. Forbi, A. O. Faneye, J. A. Otegbayo, E. Charpentier, and C. P. Muller. 2009. Phylogenetic analysis of human parvovirus B19 sequences from eleven different countries confirms the pre-dominance of genotype 1 and suggests the spread of genotype 3b. J. Clin. Microbiol. 47:3735-3738.
40. Isa, A., V. Kasprowicz, O. Norbeck, A. Loughry, K. Jeffery, K. Broliden, P. Klenerman, T. Tolfvenstam, and P. Bowness. 2005. Prolonged activation of virus-specific CD8+ T cells after acute B19 infection. PLoS Med. 2:e343.
41. Jones, M. S., A. Kapoor, V. V. Lukashov, P. Simmonds, F. Hecht, and E. Delwart. 2005. New DNA viruses identified in patients with acute viral infection syndrome. J. Virol. 79:8230-8236.
42. Jordan, J., B. Tiangco, J. Kiss, and W. Koch. 1998. Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sang. 75:97-102.
43. Jurvansuu, J., K. Raj, A. Stasiak, and P. Beard. 2005. Viral transport of DNA damage that mimics a stalled replication fork. J. Virol. 79:569-580. (Pubitemid 39648409)
44. Kaufmann, B., A. A. Simpson, and M. G. Rossmann. 2004. The structure of human parvovirus B19. Proc. Natl. Acad. Sci. U. S. A. 101:11628-11633.
45. Kerr, J. R., F. Barah, D. L. Mattey, I. Laing, S. J. Hopkins, I. V. Hutchinson, and D. A. Tyrrell. 2001. Circulating tumour necrosis factor-alpha and interferon-gamma are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue. J. Gen. Virol. 82:3011-3019.
46. Kerr, J. R., M. McCoy, B. Burke, D. L. Mattey, V. Pravica, and I. V. Hutchinson. 2003. Cytokine gene polymorphisms associated with symptomatic parvovirus B19 infection. J. Clin. Pathol. 56:725-727.
47. Kühl, U., D. Lassner, M. Pauschinger, U. M. Gross, B. Seeberg, M. Noutsias, W. Poller, and H. P. Schultheiss. 2008. Prevalence of erythrovirus genotypes in the myocardium of patients with dilated cardiomyopathy. J. Med. Virol. 80:1243-1251.
48. Kurtzman, G., N. Frickhofen, J. Kimball, D. W. Jenkins, A. W. Nienhuis, and N. S. Young. 1989. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N. Engl. J. Med. 321:519-523.
49. LaMonte, A. C., M. E. Paul, J. S. Read, M. M. Frederick, D. D. Erdman, L. L. Han, and L. J. Anderson. 2004. Persistent parvovirus B19 infection without the development of chronic anemia in HIV-infected and -unin-fected children: the Women and Infants Transmission Study. J. Infect. Dis. 189:847-851.
50. Lefrère, J. J., A. Servant-Delmas, D. Candotti, M. Mariotti, I. Thomas, Y. Brossard, F. Lefrere, R. Girot, J. P. Allain, and S. Laperche. 2005. Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood 106:2890-2895.
51. Lindton, B., T. Tolfvenstam, O. Norbeck, L. Markling, O. Ringden, M. Westgren, and K. Broliden. 2001. Recombinant parvovirus B19 empty capsids inhibit fetal hematopoietic colony formation in vitro. Fetal Diagn. Ther. 16:26-31.
52. Liu, J. M., S. W. Green, T. Shimada, and N. S. Young. 1992. A block in full-length transcript maturation in cells nonpermissive for B19 parvovirus. J. Virol. 66:4686-4692.
53. Loizou, S., J. K. Cazabon, M. J. Walport, D. Tait, and A. K. So. 1997. Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. Arthritis Rheum. 40:103-108.
54. Lukashov, V. V., and J. Goudsmit. 2001. Evolutionary relationships among parvoviruses: virus-host coevolution among autonomous primate parvoviruses and links between adeno-associated and avian parvoviruses. J. Virol. 75:2729-2740.
55. Lunardi, C., E. Tinazzi, C. Bason, M. Dolcino, R. Corrocher, and A. Puccetti. 2008. Human parvovirus B19 infection and autoimmunity. Autoimmun. Rev. 8:116-120.
56. Lunardi, C., M. Tiso, L. Borgato, L. Nanni, R. Millo, G. De Sandre, A. B. Severi, and A. Puccetti. 1998. Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties. Eur. J. Immunol. 28:936-948.
57. Lundqvist, A., T. Tolfvenstam, J. Bostic, M. Soderlund, and K. Broliden. 1999. Clinical and laboratory findings in immunocompetent patients with persistent parvovirus B19 DNA in bone marrow. Scand. J. Infect. Dis. 31:11-16.
58. Marchand, S., G. Tchernia, C. Hiesse, G. Tertian, J. Cartron, F. Kriaa, S. Boubenider, C. Goupy, D. Lecointe, and B. Charpentier. 1999. Human parvovirus B19 infection in organ transplant recipients. Clin. Transplant. 13:17-24.
59. Mitchell, L. A. 2002. Parvovirus B19 nonstructural (NS1) protein as a transactivator of interleukin-6 synthesis: common pathway in inflammatory sequelae of human parvovirus infections? J. Med. Virol. 67:267-274.
60. Moffatt, S., N. Tanaka, K. Tada, M. Nose, M. Nakamura, O. Muraoka, T. Hirano, and K. Sugamura. 1996. A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. J. Virol. 70:8485-8491.
61. Moffatt, S., N. Yaegashi, K. Tada, N. Tanaka, and K. Sugamura. 1998. Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J. Virol. 72:3018-3028.
62. Momoeda, M., S. Wong, M. Kawase, N. S. Young, and S. Kajigaya. 1994. A putative nucleoside triphosphate-binding domain in the nonstructural protein of B19 parvovirus is required for cytotoxicity. J. Virol. 68:8443-8446. (Pubitemid 24362745)
63. Morey, A. L., D. J. Ferguson, and K. A. Fleming. 1995. Combined immunocytochemistry and non-isotopic in situ hybridization for the ultrastructural investigation of human parvovirus B19 infection. Histochem. J. 27: 46-53.
64. Morey, A. L., D. J. Ferguson, and K. A. Fleming. 1993. Ultrastructural features of fetal erythroid precursors infected with parvovirus B19 in vitro: evidence of cell death by apoptosis. J. Pathol. 169:213-220.
65. Mortimer, P. P., R. K. Humphries, J. G. Moore, R. H. Purcell, and N. S. Young. 1983. A human parvovirus-like virus inhibits haematopoietic colony formation in vitro. Nature 302:426-429.
66. Mousset, S., Y. Ouadrhiri, P. Caillet-Fauquet, and J. Rommelaere. 1994. The cytotoxicity of the autonomous parvovirus minute virus of mice non-structural proteins in FR3T3 rat cells depends on oncogene expression. J. Virol. 68:6446-6453.
67. Munakata, Y., T. Saito-Ito, K. Kumura-Ishii, J. Huang, T. Kodera, T. Ishii, Y. Hirabayashi, Y. Koyanagi, and T. Sasaki. 2005. Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood 106:3449-3456.
68. Narváez Garcia, F. J., E. Domingo-Domenech, F. J. Castro-Bohorquez, M. Biosca, A. Garcia-Quintana, C. Perez-Vega, and J. Vilaseca-Momplet. 2001. Lupus-like presentation of parvovirus B19 infection. Am. J. Med. 111:573-575.
69. Nguyen, Q. T., C. Sifer, V. Schneider, F. Bernaudin, V. Auguste, and A. Garbarg-Chenon. 1998. Detection of an erythrovirus sequence distinct from B19 in a child with acute anemia. Lancet 352:1524.
70. Nguyen, Q. T., S. Wong, E. D. Heegaard, and K. E. Brown. 2002. Identification of a second novel human erythrovirus variant, A6. Virology 301:374-380.
71. Nikkari, S., A. Roivainen, P. Hannonen, T. Mottonen, R. Luukkainen, T. Yli-Jama, and P. Toivanen. 1995. Persistence of parvovirus B19 in synovial fluid and bone marrow. Ann. Rheum. Dis. 54:597-600.
72. Norja, P., K. Hokynar, L. M. Aaltonen, R. Chen, A. Ranki, E. K. Partio, O. Kiviluoto, I. Davidkin, T. Leivo, A. M. Eis-Hubinger, B. Schneider, H. P. Fischer, R. Tolba, O. Vapalahti, A. Vaheri, M. Soderlund-Venermo, and K. Hedman. 2006. Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue. Proc. Natl. Acad. Sci. U. S. A. 103:7450-7453.
73. Nüesch, J. P., and J. Rommelaere. 2006. NS1 interaction with CKII alpha: novel protein complex mediating parvovirus-induced cytotoxicity. J. Virol. 80:4729-4739.
74. Ozawa, K., J. Ayub, Y. S. Hao, G. Kurtzman, T. Shimada, and N. Young. 1987. Novel transcription map for the B19 (human) pathogenic parvovirus. J. Virol. 61:2395-2406. (Pubitemid 17097550)
75. Ozawa, K., G. Kurtzman, and N. Young. 1987. Productive infection by B19 parvovirus of human erythroid bone marrow cells in vitro. Blood 70:384-391.
76. Pallier, C., A. Greco, J. Le Junter, A. Saib, I. Vassias, and F. Morinet. 1997. The 3′ untranslated region of the B19 parvovirus capsid protein mRNAs inhibits its own mRNA translation in nonpermissive cells. J. Virol. 71:9482-9489.
77. Pasquinelli, G., F. Bonvicini, L. Foroni, N. Salfi, and G. Gallinella. 2009. Placental endothelial cells can be productively infected by parvovirus B19. J. Clin. Virol. 44:33-38.
78. Pillet, S., Z. Annan, S. Fichelson, and F. Morinet. 2003. Identification of a nonconventional motif necessary for the nuclear import of the human parvovirus B19 major capsid protein (VP2). Virology 306:25-32. (Pubitemid 36293392)
79. Pillet, S., N. Le Guyader, T. Hofer, F. NguyenKhac, M. Koken, J. T. Aubin, S. Fichelson, M. Gassmann, and F. Morinet. 2004. Hypoxia enhances human B19 erythrovirus gene expression in primary erythroid cells. Virology 327:1-7.
80. Poole, B. D., H. Zhou, A. Grote, A. Schiffenbauer, and S. J. Naides. 2006. Apoptosis of liver-derived cells induced by parvovirus B19 nonstructural protein. J. Virol. 80:4114-4121.
81. Raab, U., K. Beckenlehner, T. Lowin, H. H. Niller, S. Doyle, and S. Modrow. 2002. NS1 protein of parvovirus B19 interacts directly with DNA sequences of the p6 promoter and with the cellular transcription factors Sp1/Sp3. Virology 293:86-93.
82. Rayet, B., J. A. Lopez-Guerrero, J. Rommelaere, and C. Dinsart. 1998. Induction of programmed cell death by parvovirus H-1 in U937 cells: connection with the tumor necrosis factor alpha signalling pathway. J. Virol. 72:8893-8903.
83. Saint-Martin, J., J. J. Choulot, E. Bonnaud, and F. Morinet. 1990. Myocarditis caused by parvovirus. J. Pediatr. 116:1007-1008.
84. Sanabani, S., W. K. Neto, J. Pereira, and E. C. Sabino. 2006. Sequence variability of human erythroviruses present in bone marrow of Brazilian patients with various parvovirus B19-related hematological symptoms. J. Clin. Microbiol. 44:604-606.
85. Servant, A., S. Laperche, F. Lallemand, V. Marinho, G. De Saint Maur, J. F. Meritet, and A. Garbarg-Chenon. 2002. Genetic diversity within human erythroviruses: identification of three genotypes. J. Virol. 76:9124-9134. (Pubitemid 34919871)
86. Sheikh, A. U., and J. M. Ernest. 1995. Clinical picture and consequences of fetal parvovirus B19 infection. Ann. Med. 27:7-8.
87. Sol, N., J. Le Junter, I. Vassias, J. M. Freyssinier, A. Thomas, A. F. Prigent, B. B. Rudkin, S. Fichelson, and F. Morinet. 1999. Possible interactions between the NS-1 protein and tumor necrosis factor alpha pathways in erythroid cell apoptosis induced by human parvovirus B19. J. Virol. 73:8762-8770.
88. Tattersall, P., M. Bergoin, M. E. Bloom, K. E. Brown, and R. M. Linden. 2005. Parvoviridae, p. 353-369. In C. M. Fauquet, M. A. Mayo, J. Maniloff, U. Desselberger, and L. A. Ball (ed.), Virus taxonomy: classification and nomenclature of viruses. Eigth report of the International Committee on Taxonomy of Viruses. Elsevier/Academic Press, London, United Kingdom.
89. Tauer, T. J., M. H. Schneiderman, J. K. Vishwanatha, and S. L. Rhode. 1996. DNA double-strand break repair functions defend against parvovirus infection. J. Virol. 70:6446-6449.
90. Vassias, I., U. Hazan, Y. Michel, C. Sawa, H. Handa, L. Gouya, and F. Morinet. 1998. Regulation of human B19 parvovirus promoter expression by hGABP (E4TF1) transcription factor. J. Biol. Chem. 273:8287-8293.
91. Vihinen-Ranta, M., S. Suikkanen, and C. R. Parrish. 2004. Pathways of cell infection by parvoviruses and adeno-associated viruses. J. Virol. 78:6709-6714.
92. von Landenberg, P., H. W. Lehmann, A. Knoll, S. Dorsch, and S. Modrow. 2003. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum. 48:1939-1947.
93. von Landenberg, P., H. W. Lehmann, and S. Modrow. 2007. Human parvovirus B19 infection and antiphospholipid antibodies. Autoimmun. Rev. 6:278-285.
94. Wagner, A. D., J. J. Goronzy, E. L. Matteson, and C. M. Weyand. 1995. Systemic monocyte and T-cell activation in a patient with human parvovirus B19 infection. Mayo Clin. Proc. 70:261-265.
95. Weigel-Kelley, K. A., M. C. Yoder, and A. Srivastava. 2003. α5β1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of β1 integrin for viral entry. Blood 102:3927-3933.
96. Weigel-Van Aken, K. A. K. 2009. Pharmacological activation of guanine nucleotide exchange factors for the small GTPase Rap1 recruits high-affinity β1 integrins as coreceptors for parvovirus B19: improved ex vivo gene transfer to human erythroid progenitor cells. Hum. Gene Ther. 20:1665-1678.
97. Wong, S., N. S. Young, and K. E. Brown. 2003. Prevalence of parvovirus B19 in liver tissue: no association with fulminant hepatitis or hepatitis-associated aplastic anemia. J. Infect. Dis. 187:1581-1586.
98. Wong, S., N. Zhi, C. Filippone, K. Keyvanfar, S. Kajigaya, K. E. Brown, and N. S. Young. 2008. Ex vivo-generated CD36+ erythroid progenitors are highly permissive to human parvovirus B19 replication. J. Virol. 82:2470-2476.
99. Woolf, A. D., G. V. Campion, A. Chishick, S. Wise, B. J. Cohen, P. T. Klouda, O. Caul, and P. A. Dieppe. 1989. Clinical manifestations of human parvovirus B19 in adults. Arch. Intern. Med. 149:1153-1156.
100. Yaegashi, N., T. Niinuma, H. Chisaka, S. Uehara, S. Moffatt, K. Tada, M. Iwabuchi, Y. Matsunaga, M. Nakayama, C. Yutani, Y. Osamura, E. Hirayama, K. Okamura, K. Sugamura, and A. Yajima. 1999. Parvovirus B19 infection induces apoptosis of erythroid cells in vitro and in vivo. J. Infect. 39:68-76.
101. Zádori, Z., J. Szelei, M. C. Lacoste, Y. Li, S. Gariépy, P. Raymond, M. Allaire, I. R. Nabi, and P. Tijssen. 2001. A viral phospholipase A2 is required for parvovirus infectivity. Dev. Cell 1:291-302. (Pubitemid 33653063)
102. Zanella, A., F. Rossi, C. Cesana, A. Foresti, F. Nador, A. S. Binda, G. Lunghi, M. D. Cappellini, M. Furione, and G. Sirchia. 1995. Transfusion- transmitted human parvovirus B19 infection in a thalassemic patient. Transfusion 35:769-772.
103. Zhi, N., I. P. Mills, J. Lu, S. Wong, C. Filippone, and K. E. Brown. 2006. Molecular and functional analyses of a human parvovirus B19 infectious clone demonstrates [sic] essential roles for NS1, VP1, and the 11-kilodalton protein in virus replication and infectivity. J. Virol. 80:5941-5950.